Diabetes Clinical Trials in West Palm Beach
View 68 new treatments for Diabetes in West Palm Beach, FL. Every day, Power helps hundreds of Diabetes patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
INV 202 for Diabetic Kidney Disease
Inversago Clinic, Cooper City + 5 more
This trial tests a new drug called INV-202 in adults with Diabetic Kidney Disease caused by Type 1 or Type 2 diabetes. The goal is to see if the drug is effective, safe, and well-tolerated, and how it behaves in the body.Show More
Verified
Recruiting
Phase 2
Est. 3 - 12 Weeks
Glenn Crater, MD
Study Director
Biomarker Study for Cancer
Audubon Bioscience Clinic, West Palm Beach + 1 more
Study purpose: to explore the entire spectrum of proteomic and genomic changes (amongst others) involved in diseases and in healthy/control populations. The Study is designed to discover biomarkers, develop and validate diagnostic assays, instruments and therapeutics as well as other medical research. Specifically, researchers may analyze proteins, RNA, DNA copy number changes, including large and small (1,000-100,000 kb) scale rearrangements, transcription profiles, epigenetic modifications, sequence variation, and sequence in both diseased tissue and case-matched germline DNA from Subjects.Show More
Verified
Waitlist
No Placebo Trial
N/A
Est. 3 - 6 Weeks
Unregistered Study Lead
Research Team
ILUVIEN® Implant for Diabetic Macular Edema
Alimera Sciences Clinic, Palm Beach Gardens + 1 more
This is a randomized, masked, active-controlled, parallel-group, multi-center study that will assess the efficacy of ILUVIEN as a baseline therapy in the treatment of Center Involving DME (CI-DME). The study will enroll patients who are either treatment naïve or have not received any DME treatments for the preceding 12 months as documented in medical records. Patients who received DME treatment \>12 months before screening, must not have received \>4 intravitreal injections. The study will compare 2 treatment regimens: ILUVIEN intravitreal implant (0.19 mg) followed by supplemental aflibercept as needed per protocol criteria (2 mg/0.05 mL), compared to intravitreal aflibercept loading dose (2 mg administered by intravitreal injection every 4 weeks for 5 consecutive doses) followed by supplemental aflibercept as needed per protocol criteria (2 mg/0.05 mL).Show More
Waitlist
No Placebo Trial
Phase 4
Est. 6 - 12 Weeks
Samer Kaba, MD
Study Chair
Tirzepatide for Type 2 Diabetes
Eli Lilly Clinic, Margate + 2 more
This study aims to investigate the efficacy and safety of tirzepatide in participants with type 2 diabetes (T2D) compared to other existing treatment options when treatment is initiated early.Show More
Recruiting
No Placebo Trial
Phase 4
Est. 6 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Faricimab for Diabetic Macular Edema
Genentech Clinic, Plantation + 1 more
This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treated with faricimab. The study population will consist of participants ≥18 years of age who self-identify as Black/African American, Hispanic/Latino American, or Native American/Alaska Native/Native Hawaiian or other Pacific Islander; in addition, a cohort of Asian Indian participants will be enrolled in India.Show More
Recruiting
No Placebo Trial
Phase 4
Est. 4 - 6 Weeks
Clinical Trials
Study Director
Naltrexone + Bupropion for Obesity
Currax Clinic, Pembroke Pines + 1 more
This trial studies the effects of a medication combination (naltrexone and bupropion) on heart health. It targets patients to see if this treatment increases the risk of major heart problems. The study also includes advice on diet and exercise. Naltrexone and bupropion have been used in combination for weight loss, but they have been associated with various adverse effects, including neuropsychiatric disorders and cardiovascular risks.Show More
Recruiting
Phase 4
Est. 4 - 6 Weeks
Unregistered Study Lead
Research Team
Mifepristone for Type 2 Diabetes
Corcept Clinic, Fort Lauderdale + 1 more
This trial is testing mifepristone, a medication that blocks cortisol, in patients with hard-to-control type 2 diabetes and high cortisol levels. The goal is to see if mifepristone can help manage their blood sugar better than standard treatments alone. Mifepristone has been studied for various conditions including Cushing's syndrome, psychotic depression, and cognitive decline in Alzheimer's disease.Show More
Recruiting
Phase 4
Est. 3 - 6 Weeks
Daniel Einhorn, MD
Study Director
Ranibizumab PDS Implant for Diabetic Retinopathy
Hoffmann-La Roche Clinic, Plantation + 1 more
Study GR41675 is a Multicenter, Randomized Study in Participants with Diabetic Retinopathy (DR) Without Center-Involved Diabetic Macular Edema (CI-DME) to Evaluate the Efficacy, Safety of the Port Delivery System with Ranibizumab (PDS) Relative to the Comparator ArmShow More
Waitlist
No Placebo Trial
Phase 3
Est. 5 - 8 Weeks
Clinical Trials
Study Director
Orforglipron for Obesity
Eli Lilly Clinic, Margate + 2 more
This trial will test a daily pill called orforglipron to see if it helps people who are overweight or obese and have type 2 diabetes lose weight. The study will last over a year and involve multiple visits.Show More
Waitlist
Phase 3
Est. 3 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
CagriSema for Type 2 Diabetes
Novo Nordisk Clinic, Hollywood + 1 more
This study will look at how much CagriSema helps participants with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a "dummy" medicine (also called "placebo") that has no effect on the body. Participants will get either CagriSema or "dummy" medicine. Which treatment participants get is decided by chance. For each participant, the study will last for about one year.Show More
Recruiting
Phase 3
Est. 5 - 8 Weeks
Clinical Transparency (dept. 2834)
Study Director
Page 1 of 6
Frequently Asked Questions
Explore related conditions